Animal Experimental Study on the Efficacy of Traditional Chinese Medicine Syndrome Differentiation Treatment for PCOS Based on Core Indicator Target Evaluation

doi:10.12280/gjszjk.20260079

Abstract

Abstract:

Objective: To evaluate the efficacy of Cangfu Daotan Decoction and Zhibai Dihuang Decoction in the differential treatment of polycystic ovary syndrome (PCOS), based on the core indicator target evaluation. Methods: Using a random number table method, 6 rats were randomly selected from 54 female SD rats as the blank group (no modeling). The remaining rats were randomly divided into groups for the construction of obese PCOS and non-obese PCOS models, with 24 rats in each category. Each model category was further divided into the control group (obese control group/non-obese control group), the Diane-35 group, the Cangfu Daotan Decoction group and the Zhibai Dihuang Decoction group, with 6 rats in each group. The rat morphology, body mass, estrous cycle, ovarian morphology, serum sex hormones, and glucose and lipid metabolism levels were compared. Results: After modeling, except for the blank group, the rats in both the obese and non-obese control groups lacked a regular estrous cycle. The obese PCOS rats exhibited characteristics of spleen deficiency and phlegm-dampness syndrome, while the non-obese PCOS rats showed characteristics of kidney yin deficiency syndrome. After modeling, serum testosterone (T), luteinizing hormone (LH), fasting blood glucose (FBG), fasting insulin (FINS), total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) in the obese and non-obese control groups were significantly higher than those in the blank group. LH in the non-obese control group was significantly higher than in the obese control group, while TC, TG, and LDL-C in the obese control group were significantly higher than in the non-obese control group (all P<0.05). After administration, serum T and LH in the Diane-35 group and Cangfu Daotan Decoction group were significantly lower than in the obese control group, and FINS, TC, TG, LDL-C, ovarian volume, and mass in the Cangfu Daotan Decoction group were lower than in the obese control group (all P<0.05). In non-obese PCOS rats, after administration, serum T and LH in the Diane-35 group and Zhibai Dihuang Decoction group were significantly lower than those in the non-obese control group, and FINS, TG, LDL-C, ovarian volume, and mass in the Zhibai Dihuang Decoction group were lower than those in the non-obese control group (all P<0.05). Conclusions: This study experimentally confirms that obesity can serve as a typical characteristic for the differential diagnosis of PCOS. The treatment of obese PCOS with Cangfu Daotan Decoction and non-obese PCOS with Zhibai Dihuang Decoction yields significant effects. This highlights the wisdom of the traditional Chinese medicine principle of "treating the same disease with different methods" and provides animal experimental data supporting the syndrome differentiation and classification treatment of PCOS in traditional Chinese medicine.

Key words: Polycystic ovary syndrome, Syndrome differentiation classification, Phlegm dampness due to spleen deficiency, Syndrome of deficiency of kidney yin, Obesity, Animal experimentation

LIN Kai-li, LIU Yin, WANG Jiao-jian, SONG Dian-rong, ZHANG Wei, LU Di. Animal Experimental Study on the Efficacy of Traditional Chinese Medicine Syndrome Differentiation Treatment for PCOS Based on Core Indicator Target Evaluation[J]. Journal of International Reproductive Health/Family Planning, 2026, 45(2): 89-96.

Figures/Tables 11

References 11

[1]	Bahri Khomami M, Shorakae S, Hashemi S, et al. Systematic review and meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome[J]. Nat Commun, 2024, 15(1):5591. doi: 10.1038/s41467-024-49749-1. pmid: 38965226
[2]	Gao Y, Liu H, Qiao L, et al. Study of Burden in Polycystic Ovary Syndrome at Global, Regional, and National Levels from 1990 to 2019[J]. Healthcare(Basel), 2023, 11(4)562. 10.3390/healthcare11040562.
[3]	Rudnicka E, Suchta K, Grymowicz M, et al. Chronic Low Grade Inflammation in Pathogenesis of PCOS[J]. Int J Mol Sci, 2021, 22(7):3789. doi: 10.3390/ijms22073789.
[4]	Dapas M, Lin FTJ, Nadkarni GN, et al. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis[J]. PLoS Med, 2020, 17(6):e1003132. doi: 10.1371/journal.pmed.1003132.
[5]	朱震亨. 丹溪心法[M]. 北京: 人民卫生出版社, 2005:315.
[6]	李泉洋, 郝亚芳, 吴国泰, 等. 基于方剂反证策略的多囊卵巢综合征肾虚血瘀证大鼠模型构建与评价[J]. 中国临床药理学杂志, 2025, 41(8):1108-1113.
[7]	Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome[J]. J Clin Endocrinol Metab, 2023, 108(10):2447-2469. doi: 10.1210/clinem/dgad463. pmid: 37580314
[8]	许叔微. 类证普济本事方续集[M]//裘庆元. 三三医书. 北京: 中国中医药出版社, 1998:851.
[9]	张丽丽, 张子月, 许彩凤. 从窠囊理论探讨多囊卵巢综合征所致不孕[J]. 中医药临床杂志, 2023, 35(6):1066-1069. doi: 10.16448/j.cjtcm.2023.0605.
[10]	何梦瑶. 医碥[M]. 北京: 中国中医药出版社, 2009:314.
[11]	刘寨华, 张宇鹏, 杨威. 论《内经》中“精”字源流及其涵义[J]. 中国中医基础医学杂志, 2007, 13(10):731-732.

组别	n	肥胖型PCOS大鼠		非肥胖型PCOS大鼠
组别	n	造模前（g）	造模后（g）	造模前（g）	造模后（g）
空白组	6	208.60±13.27	253.93±8.35*	208.60±13.27	253.93±8.35*
对照组	6	209.55±14.90	287.90±21.94^a	207.50±17.69	221.75±29.82^a
达英-35组	6	207.90±11.82	291.70±29.21^a	207.45±8.31	221.67±24.74^a
苍附导痰汤组	6	211.85±12.33	293.80±14.25^a	208.30±16.07	224.17±23.42^a
知柏地黄汤组	6	212.90±7.09	300.60±18.03^a	204.90±17.35	222.10±22.39^a
F		0.374	5.744	0.157	6.386
P		0.825	0.002	0.955	0.001

组别	n	肥胖型PCOS大鼠		非肥胖型PCOS大鼠
组别	n	造模前（g）	造模后（g）	造模前（g）	造模后（g）
空白组	6	208.60±13.27	253.93±8.35*	208.60±13.27	253.93±8.35*
对照组	6	209.55±14.90	287.90±21.94^a	207.50±17.69	221.75±29.82^a
达英-35组	6	207.90±11.82	291.70±29.21^a	207.45±8.31	221.67±24.74^a
苍附导痰汤组	6	211.85±12.33	293.80±14.25^a	208.30±16.07	224.17±23.42^a
知柏地黄汤组	6	212.90±7.09	300.60±18.03^a	204.90±17.35	222.10±22.39^a
F		0.374	5.744	0.157	6.386
P		0.825	0.002	0.955	0.001

组别	n	T（nmol/L）	LH（U/L）	FSH（U/L）	P（ng/mL）	PRL（ng/mL）	E₂（pmol/L）
空白组	6	4.76±0.24	9.25±1.45	4.52±0.21	0.85±0.25	11.36±0.79	28.19±1.83
肥胖对照组	6	6.14± 0.29^a	11.47±1.13^a	4.34±0.32	0.83±0.19	12.11±1.24	27.11±2.77
非肥胖对照组	6	6.43±0.49^a	14.16±1.37^ab	4.22±0.15	0.79±0.22	12.21±1.25	28.28±2.55
F		36.785	20.714	2.526	0.207	1.514	0.437
P		0.000	0.000	0.113	0.816	0.252	0.654

组别	n	T（nmol/L）	LH（U/L）	FSH（U/L）	P（ng/mL）	PRL（ng/mL）	E₂（pmol/L）
空白组	6	4.76±0.24	9.25±1.45	4.52±0.21	0.85±0.25	11.36±0.79	28.19±1.83
肥胖对照组	6	6.14± 0.29^a	11.47±1.13^a	4.34±0.32	0.83±0.19	12.11±1.24	27.11±2.77
非肥胖对照组	6	6.43±0.49^a	14.16±1.37^ab	4.22±0.15	0.79±0.22	12.21±1.25	28.28±2.55
F		36.785	20.714	2.526	0.207	1.514	0.437
P		0.000	0.000	0.113	0.816	0.252	0.654

组别	n	FBG（mmol/L）	FINS（mIU/L）	TC（mmol/L）	TG（mmol/L）	LDL-C（mmol/L）
空白组	6	4.13±0.23	10.43±0.59	1.04±0.13	1.00±0.10	0.41±0.03
肥胖对照组	6	5.15±0.28^a	12.79±0.99^a	1.57±0.06^a	1.46±0.24^a	0.61±0.03^a
非肥胖对照组	6	5.38±0.40^a	13.67±0.64^a	1.40±0.08^ab	1.18±0.04^ab	0.56±0.04^ab
F		39.397	4.328	50.002	13.250	65.233
P		0.000	0.031	0.000	0.000	0.000